Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

173 projects found matching your search criteria :

  1. Functional nanomaterials based on drug–lipid–ligands as targeted delivery systems for anticancer agents in lung adenocar...

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Piotr Paweł Szyk

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  2. Development of novel 1,3-selenazol-2-one derivatives incorporated into self-emulsifying drug delivery systems as a strat...

    Call: OPUS 29 , Panel: NZ7

    Principal investigator: dr hab. Robert Czarnomysy

    Uniwersytet Medyczny w Białymstoku

  3. Dual cell cycle blockade and immune checkpoint inhibition as a potential strategy of sequential anticancer therapy

    Call: PRELUDIUM 24 , Panel: NZ7

    Principal investigator: Alicja Stanisława Słota

    Uniwersytet Jagielloński

  4. Application of Griesbaum Co-ozonolysis in the Synthesis of Iron-Sensitive Conjugates of 1,2,4-Trioxolanes as Anticancer ...

    Call: OPUS 29 , Panel: ST5

    Principal investigator: prof. Adam Włodzimierz Huczyński

    Uniwersytet im. Adama Mickiewicza w Poznaniu

  5. Mind the gap! Plasmonic nanocavity for spectroscopic trapping of local molecularrearrangements in DNA upon epigenetic mo...

    Call: OPUS 28 , Panel: ST4

    Principal investigator: prof. Ewelina Wioletta Lipiec

    Uniwersytet Jagielloński

  6. Where Inhibition is not Enough- Development of Innovative Compounds for Targeted Degradation of Extracellular and Membra...

    Call: OPUS 28 (LAP) , Panel: NZ5

    Principal investigator: dr Marcin Skoreński

    Politechnika Wrocławska

  7. Application of bioconjugation strategy to the synthesis of anticancer Trojan horses

    Call: OPUS 28 , Panel: ST5

    Principal investigator: dr hab. Michał Piotr Antoszczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu

  8. FA-PROTACs - Design and Synthesis of Compounds Based on Folic Acid for Degradation of Enzyme Involved in Folate Metaboli...

    Call: SONATA 20 , Panel: NZ5

    Principal investigator: dr Mateusz Daśko

    Politechnika Gdańska

  9. Enzymatic preparation of new dehydrogenated pentacyclic triterpenes of pharmacological importance

    Call: SONATA BIS 14 , Panel: ST4

    Principal investigator: dr Agnieszka Maria Wojtkiewicz

    Instytut Katalizy i Fizykochemii Powierzchni im. Jerzego Habera PAN

  10. Canonical and non-canonical roles of DDK in oncogenesis: a cornerstone for the development of novel, potent anticancer t...

    Call: SONATA BIS 14 , Panel: NZ3

    Principal investigator: dr Jan Marian Suski

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  11. EGR1 Protein: A Key Factor in Cellular Homeostasis?

    Call: PRELUDIUM 23 , Panel: NZ3

    Principal investigator: Marta Leśniczak-Staszak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  12. The two are better than one - biferrocenyl ROS generators as intelligent anticancer agents

    Call: OPUS 27 , Panel: ST5

    Principal investigator: prof. Konrad Maciej Kowalski

    Uniwersytet Łódzki

  13. Development and characterization of novel multitargeted organometallic tubulin polymerization inhibitors for enhancing t...

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr hab. Damian Nestor Plażuk

    Uniwersytet Łódzki

  14. Potential pharmacological strategies aimed at alleviating cognitive dysfunctions accompanying oncological therapy while ...

    Call: OPUS 26 , Panel: NZ5

    Principal investigator: dr hab. Joanna Monika Wierońska

    Instytut Farmakologii PAN

  15. Tumor viscoelasticity as a central player in glioblastoma treatment - towards mechanopharmacology

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Pogoda

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego PAN

  16. Integrated multi-omics approach to accelerate anticancer drug discovery by targeting metabolic reprogramming in human co...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Danuta Dudzik

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

  17. Functional and structural analysis of anticancer drugs as protein biosynthesis inhibitors

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Witold Szaflarski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Medyczny

  18. Design and microfluidic synthesis of hybrid nanocarriers stabilized by novel sugar surfactants as a potential anticancer...

    Call: SONATA BIS 13 , Panel: ST4

    Principal investigator: dr hab. Urszula Jolanta Bazylińska

    Politechnika Wrocławska

  19. Design and Development of Serine Hydroxymethyltransferase-2 (SHMT2) Inhibitors Blocking Tumor Growth

    Call: SONATA BIS 13 , Panel: NZ7

    Principal investigator: dr hab. Miłosz Ruszkowski

    Instytut Chemii Bioorganicznej PAN

  20. Three to tango - biomaterials with therapeutic and regenerative multifunctionality

    Call: SONATA BIS 13 , Panel: ST11

    Principal investigator: dr Marzena Krystyna Fandzloch

    Instytut Niskich Temperatur i Badań Strukturalnych im. Włodzimierza Trzebiatowskiego PAN

  21. Compounds modulating function of telomeric proteins TRF1 and TRF2

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Maciej Wojciech Bagiński

    Politechnika Gdańska, Wydział Chemiczny

  22. In vitro anticancer screening of triterpene saponins isolated from beetroot (Beta vulgaris L.) by countercurrent chromat...

    Call: PRELUDIUM 22 , Panel: NZ9

    Principal investigator: Anna Maria Tekieli

    Politechnika Krakowska im. Tadeusza Kościuszki, Wydział Inżynierii i Technologii Chemicznej

  23. Anticancer potential of TMPyP4 porphyrin in breast cancer photodynamic therapy and evaluation of the treatment safety

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Błażej Rubiś

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  24. Chiral hybrids of quinones and quinols with double anticancer and antimicrobial activity against drug-resistant pathogen...

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Ryszard Józef Ostaszewski

    Instytut Chemii Organicznej Polska Akademia Nauk

  25. Myeloid cell subpopulations as a source of effector cells for anticancer therapies using CAR chimeric receptors

    Call: OPUS 25 , Panel: NZ6

    Principal investigator: dr hab. Angelika Muchowicz

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  26. From simple alkaloids to potentially anticancer Ir(III) and Ru(II) complexes supported by the magnetic nanoparticles.

    Call: PRELUDIUM 22 , Panel: ST4

    Principal investigator: Daria Bogumiła Wojtala

    Uniwersytet Wrocławski, Wydział Chemii

  27. Design, Synthesis and Characterization of Functionalized 1,2,4-Trioxanes/Trioxepanes for Antimalarial and Anticancer Use

    Call: SONATINA 7 , Panel: NZ7

    Principal investigator: dr Mohit Kumar Tiwari

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  28. CHIRAL RHENIUM AND RHODIUM COMPLEXES OF ANTICANCER AND ANTIBACTERIAL ACTIVITY: SYNTHESIS, ACTIVITY, AND PHYSICOCHEMICAL ...

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: prof. Jan Czesław Dobrowolski

    Narodowy Instytut Leków

  29. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  30. Exploring the anticancer, antibacterial and antifungal potential and underlying mechanism of action of plants used in Po...

    Call: SONATA 18 , Panel: NZ9

    Principal investigator: dr Kamila Jadwiga Rachwał

    Uniwersytet Przyrodniczy w Lublinie

  31. Fungal bioactive substances with targeted pro-health potential - the role ofinteractions, bioavailability and bioavailab...

    Call: OPUS 23 , Panel: NZ9

    Principal investigator: prof. Michał Świeca

    Uniwersytet Przyrodniczy w Lublinie, Wydział Nauk o Żywności i Biotechnologii

  32. Anticancer drug candidates from Nostoc edaphicum CCNP1411 and Pseudanabaena galeata CCNP1313 (CYANOCRAB)

    Call: OPUS 23 , Panel: NZ9

    Principal investigator: prof. Hanna Jurata Mazur-Marzec

    Uniwersytet Gdański, Wydział Chemii

  33. Pancreatic cancer oxygenation as a prognostic marker during anticancer therapy

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr Martyna Krzykawska-Serda

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  34. Identification of anticancer phytochemicals of dandelion root (Taraxaci radix) based on metabolomics and bioassay-guided...

    Call: PRELUDIUM 21 , Panel: NZ9

    Principal investigator: Sylwia Irena Pawelec

    Instytut Uprawy Nawożenia i Gleboznawstwa - Państwowy Instytut Badawczy

  35. Enzyme Responsive Nanoscale Supramolecular Capsules with Application in Anticancer Drug Delivery

    Call: POLONEZ BIS 2 , Panel: ST4

    Principal investigator: dr Venkateswarulu Mangili

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Centrum Zaawansowanych Technologii

  36. Bioresorbable, electrospun nonwoven as a multi-drug delivery system for a combination glioblastoma therapy

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Monika Anna Musiał-Kulik

    Centrum Materiałów Polimerowych i Węglowych PAN

  37. Search for Inhibitors of Human δ1-Pyrroline-5-Carboxylate Reductase 1 (PYCR1) as Lead Molecules for the Development of N...

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: dr hab. Miłosz Ruszkowski

    Instytut Chemii Bioorganicznej PAN

  38. Heterocyclization of benzenoid ansamycins core as useful strategy for designing anticancer agents

    Call: PRELUDIUM 20 , Panel: ST4

    Principal investigator: Natalia Anna Skrzypczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Chemii

  39. Anticancer activity of novel derivatives of 9,10-Anthraquinone Dithiocarbamates

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Natalia Anna Maciejewska

    Politechnika Gdańska

  40. Evaluation of NOTCH1- and NOTCH3-dependent anticancer drug resistance in a 2D and 3D model of Head and Neck Squamous Cel...

    Call: PRELUDIUM 20 , Panel: NZ5

    Principal investigator: dr Joanna Elżbieta Kałafut

    Uniwersytet Medyczny w Lublinie

  41. Switchable with visible light cisplatin analogs and complexes of selected transition metals - photochemical and anticanc...

    Call: OPUS 21 , Panel: NZ7

    Principal investigator: prof. Krzysztof Szczubiałka

    Uniwersytet Jagielloński, Wydział Chemii

  42. Mitochondria-targeting conjugates as a new anticancer agents

    Call: OPUS 21 , Panel: ST4

    Principal investigator: prof. Adam Włodzimierz Huczyński

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Chemii

  43. Development of new implantable drug forms, biodegradable nanofibers containing selected betulin derivatives in order to ...

    Call: OPUS 21 , Panel: NZ7

    Principal investigator: prof. Janusz Edward Kasperczyk

    Śląski Uniwersytet Medyczny w Katowicach, Wydział Nauk Farmaceutycznych w Sosnowcu

  44. Thrombin binding aptamer with expanded chemical diversity as potential anticoagulant and anticancer agent

    Call: OPUS 21 , Panel: NZ7

    Principal investigator: dr Weronika Paulina Kotkowiak

    Instytut Chemii Bioorganicznej PAN

  45. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer...

    Call: SONATINA 5 , Panel: NZ3

    Principal investigator: dr Karolina Anna Staniak

    Politechnika Warszawska, Wydział Chemiczny

  46. Preparation and evaluation of biological activity of new biotinylated hop flavonoid analogues.

    Call: SONATA 16 , Panel: NZ9

    Principal investigator: dr hab. Monika Stompor-Gorący

    Uniwersytet Rzeszowski

  47. The use of iodoquinolines for biostimulation and biofortification of selected vegetables in iodine and investigation of ...

    Call: OPUS 19 , Panel: NZ9

    Principal investigator: dr hab. Aneta Agnieszka Koronowicz

    Uniwersytet Rolniczy im. Hugona Kołłątaja w Krakowie, Wydział Biotechnologii i Ogrodnictwa

  48. Increasing the precision of chimeric antigen receptor (CAR)-mediated anticancer immunotherapy by using the chemokine-ind...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny

  49. Photodynamic therapy combined with PD-1/PD-L1 blockade immunotherapy: new possibilities for the treatment of immunogenic...

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: dr hab. Janusz Marcin Dąbrowski

    Uniwersytet Jagielloński, Wydział Chemii

  50. DNA polymerase θ as a novel therapeutic target in personalized anticancer therapy

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Śliwiński

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy